Works about CANAGLIFLOZIN

Results: 691

Latest news: Tirzepatide for type 2 diabetes; cardio-diabetes clinics; and cardiorenal biomarkers in DKD: Stay abreast of the latest news that could impact diabetes nursing.

Published in:: Journal of Diabetes Nursing, 2023, v. 27, n. 5, p. 1
Publication type:: Article

Canagliflozin receives licence to treat diabetic kidney disease.

Published in:: Journal of Diabetes Nursing, 2020, v. 24, n. 4, p. 1
Publication type:: Article

Meeting report: ADA 80<sup>th</sup> Scientific Sessions.

Published in:: Journal of Diabetes Nursing, 2020, v. 24, n. 4, p. 1
Publication type:: Article

CREDENCE trial: Canagliflozin effective for primary cardiovascular protection.

Published in:: Journal of Diabetes Nursing, 2019, v. 23, n. 3, p. 2
Publication type:: Article

Canagliflozin shows renoprotective effect.

Published in:: Journal of Diabetes Nursing, 2019, v. 23, n. 2, p. 1
Publication type:: Article

Breaking news in cardiovascular outcome trials; empagliflozin and stroke; and glycaemic variability in type 1 diabetes.

Published in:: Journal of Diabetes Nursing, 2017, v. 21, n. 6, p. 223
Publication type:: Article

CANVAS and EMPA-REG findings support cardiovascular safety of SGLT2 inhibitors.

Published in:

Journal of Diabetes Nursing, 2017, v. 21, n. 6, p. 193

By:

Hill, Jill

Publication type:

Article

Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.

Published in:

2020

By:

Musso, Giovanni;
Sircana, Antonio;
Saba, Francesca;
Cassader, Maurizio;
Gambino, Roberto

Publication type:

journal article

Canagliflozin stability study and ecofriendly chromatographic determination of its degradation product: A comparative study.

Published in:

Journal of Separation Science, 2018, v. 41, n. 4, p. 822, doi. 10.1002/jssc.201700976

By:

Emam, Aml A.

Publication type:

Article

Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis.

Published in:

Clinical Rheumatology, 2023, v. 42, n. 9, p. 2469, doi. 10.1007/s10067-023-06647-z

By:

Wood, David T.;
Waterbury, Nancee V.;
Lund, Brian C.

Publication type:

Article

Development and Validation of Stability-Indicating RPHplc Method for Simultaneous Determination of Canagliflozin and Metformin in Fixed-Dose Combination.

Published in:

Journal of Research in Pharmacy, 2023, v. 27, n. 3, p. 1234, doi. 10.29228/jrp.412

By:

KHAN, Nayeem;
AHMED, Aejaz;
QAZI, Majaz;
ANSARI, Yaasir Ahmed;
SHAIKH, Afsar;
BADGIRE, Ayyaj A.;
SALMAN, Mohd;
KHAN, Noosrat Jahan

Publication type:

Article

Finerenone in SGLT-2 Inhibitors Era: Current Positioning in Diabetic Kidney Disease.

Published in:

Clinical Diabetology, 2022, v. 11, n. 6, p. 357, doi. 10.5603/DK.a2022.0041

By:

Singh, Awadhesh Kumar;
Singh, Ritu;
Shah, Viral N.;
Misra, Anoop

Publication type:

Article

Survey to Specify SGLT2 Inhibitor Choice in T2DM Management.

Published in:

Clinical Diabetology, 2022, v. 11, n. 5, p. 326, doi. 10.5603/DK.a2022.0042

By:

Ghosal, Samit;
Joshi, Radhika M.;
Iyer, Rahul N.;
Adsule, Samir M.

Publication type:

Article

Harmful versus beneficial effects of using short-term combined oral antidiabetic therapy: An open-label comparative clinical trial.

Published in:

Clinical Diabetology, 2021, v. 10, n. 4, p. 349

By:

Baito, Qoyama N.;
Alhassani, Ansam N.;
Al-Nimer, Marwan S. M.

Publication type:

Article

Glycaemic and weight-loss outcomes of graded doses of canagliflozin in type 2 diabetes -- a real-world study.

Published in:

Clinical Diabetology, 2020, v. 9, n. 6, p. 442, doi. 10.5603/DK.2020.0044

By:

Dutta, Deep;
Sharma, Meha;
Dhall, Anil;
Aggarwal, Sameer;
Khandelwal, Deepak

Publication type:

Article

A real-world retrospective evaluation of glycaemic control and weight loss in patients with type 2 diabetes mellitus treated with canagliflozin 100 mg and canagliflozin 300 mg in an Indian setting.

Published in:

Clinical Diabetology, 2020, v. 9, n. 5, p. 300, doi. 10.5603/DK.2020.0031

By:

Mukherjee, Poulomi;
Roychoudhury, Soumyabrata;
Majumder, Anirban

Publication type:

Article

Role of SGLT-2 Inhibitors In Diabetic Nephropathy.

Published in:

Multi-Knowledge Electronic Comprehensive Journal For Education & Science Publications (MECSJ), 2021, n. 39, p. 1

By:

Raja, Maddasar Ali;
AlTarawneh, Shadi Suleiman

Publication type:

Article

A study of canagliflozin on post prandial blood sugar control.

Published in:

Indian Journal of Basic & Applied Medical Research, 2021, v. 10, n. 3, p. 18, doi. 10.36848/IJBAMR/2020/29215.55560

By:

P., SAI SEKHAR;
RONGALI, APPALA NAIDU

Publication type:

Article

Contemporary Use of Sodium Glucose Co-Transporter 2 Inhibitors in Hospitalized Heart Failure Patients: A "Real-World" Experience.

Published in:

Journal of Clinical Medicine, 2024, v. 13, n. 12, p. 3562, doi. 10.3390/jcm13123562

By:

Xanthopoulos, Andrew;
Katsiadas, Nikolaos;
Giamouzis, Grigorios;
Vangelakou, Kleoniki;
Balaskas, Dimitris;
Papamichalis, Michail;
Bourazana, Angeliki;
Chrysakis, Nikolaos;
Kiokas, Sotirios;
Kourek, Christos;
Briasoulis, Alexandros;
Skopeliti, Niki;
Makaritsis, Konstantinos P.;
Parissis, John;
Stefanidis, Ioannis;
Magouliotis, Dimitrios;
Athanasiou, Thanos;
Triposkiadis, Filippos;
Skoularigis, John

Publication type:

Article

Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 13, p. 4248, doi. 10.3390/jcm12134248

By:

Gorgojo-Martinez, Juan J.;
Ferreira-Ocampo, Pablo José;
Galdón Sanz-Pastor, Alba;
Cárdenas-Salas, Jersy;
Antón-Bravo, Teresa;
Brito-Sanfiel, Miguel;
Almodóvar-Ruiz, Francisca

Publication type:

Article

Association of Sodium-Glucose Cotransporter 2 Inhibitors with Osteomyelitis and Other Lower Limb Safety Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 12, p. 3958, doi. 10.3390/jcm12123958

By:

Nani, Alessandro;
Carrara, Federica;
Paulesu, Chiara Maria Eleonora;
Dalle Fratte, Chiara;
Padroni, Matteo;
Enisci, Silvia;
Bilancio, Maria Concetta;
Romio, Maria Silvia;
Bertuzzi, Federico;
Pintaudi, Basilio

Publication type:

Article

Bempedoic Acid, an Inhibitor of Cholesterol Biosynthesis, Reduces Cardiovascular Events.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 10, p. 3463, doi. 10.3390/jcm12103463

By:

Jialal, Ishwarlal;
Olatunbosun, Samuel

Publication type:

Article

Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 9, p. 3247, doi. 10.3390/jcm12093247

By:

Peters, Kirsten E.;
Bringans, Scott D.;
O'Neill, Ronan S.;
Lumbantobing, Tasha S. C.;
Lui, James K. C.;
Davis, Timothy M. E.;
Hansen, Michael K.;
Lipscombe, Richard J.

Publication type:

Article

Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 21, p. 6544, doi. 10.3390/jcm11216544

By:

Yaribeygi, Habib;
Maleki, Mina;
Reiner, Željko;
Jamialahmadi, Tannaz;
Sahebkar, Amirhossein

Publication type:

Article

Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-Wecan Study.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 19, p. 5622, doi. 10.3390/jcm11195622

By:

Gorgojo-Martinez, Juan J.;
Brito-Sanfiel, Miguel;
Antón-Bravo, Teresa;
Galdón Sanz-Pastor, Alba;
Wong-Cruz, Jaime;
Gargallo Fernández, Manuel A.

Publication type:

Article

Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 1, p. 137, doi. 10.3390/jcm11010137

By:

Xu, Jing;
Hirai, Taro;
Koya, Daisuke;
Kitada, Munehiro

Publication type:

Article

SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review.

Published in:

Journal of Clinical Medicine, 2021, v. 10, n. 9, p. 2036, doi. 10.3390/jcm10092036

By:

Lu, Henri;
Lu, Hortense;
Kosinski, Christophe;
Wojtusciszyn, Anne;
Zanchi, Anne;
Carron, Pierre-Nicolas;
Müller, Martin;
Meyer, Philippe;
Martin, Jehan;
Muller, Olivier;
Hullin, Roger;
Costantino, Giorgio

Publication type:

Article

De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study.

Published in:

Journal of Clinical Medicine, 2021, v. 10, n. 9, p. 2013, doi. 10.3390/jcm10092013

By:

Pérez-Belmonte, Luis M.;
Ricci, Michele;
Sanz-Cánovas, Jaime;
Cobos-Palacios, Lidia;
López-Carmona, María D.;
Ruiz-Moreno, M. Isabel;
Millán-Gómez, Mercedes;
Bernal-López, M. Rosa;
Jansen-Chaparro, Sergio;
Gómez-Huelgas, Ricardo;
Gladysheva, Inna P.

Publication type:

Article

Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study.

Published in:

Journal of Clinical Medicine, 2021, v. 10, n. 3, p. 505, doi. 10.3390/jcm10030505

By:

Martín, Ernesto;
López-Aguilera, José;
González-Manzanares, Rafael;
Anguita, Manuel;
Gutiérrez, Guillermo;
Luque, Aurora;
Paredes, Nick;
Oneto, Jesús;
Perea, Jorge;
Castillo, Juan Carlos;
Farre, Nuria

Publication type:

Article

Medroxyprogesterone Reverses Tolerable Dose Metformin-Induced Inhibition of Invasion via Matrix Metallopeptidase-9 and Transforming Growth Factor-β1 in KLE Endometrial Cancer Cells.

Published in:

Journal of Clinical Medicine, 2020, v. 9, n. 11, p. 3585, doi. 10.3390/jcm9113585

By:

Suh, Dong Hoon;
Lee, Sunray;
Park, Hyun-Sook;
Park, Noh Hyun

Publication type:

Article

Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study.

Published in:

Journal of Clinical Medicine, 2020, v. 9, n. 7, p. 2275, doi. 10.3390/jcm9072275

By:

Gorgojo-Martínez, Juan J.;
Gargallo-Fernández, Manuel A.;
Galdón Sanz-Pastor, Alba;
Antón-Bravo, Teresa;
Brito-Sanfiel, Miguel;
Wong-Cruz, Jaime

Publication type:

Article

Canagliflozin Delays Aging of HUVECs Induced by Palmitic Acid via the ROS/p38/JNK Pathway.

Published in:

Antioxidants, 2023, v. 12, n. 4, p. 838, doi. 10.3390/antiox12040838

By:

Hao, Wenhui;
Shan, Wenjie;
Wan, Fang;
Luo, Jingyi;
Niu, Yaoyun;
Zhou, Jin;
Zhang, Yaou;
Xu, Naihan;
Xie, Weidong

Publication type:

Article

Evaluation of Antidiabetic Activity of Novel Triterpenoids Isolated From Ethyl Acetate Extract of Cassia fistula Stem Bark Through in vivo and in silico Analysis.

Published in:

2024

By:

S., Indu;
Illangovan, Sujatha;
A., Clara Mary;
S., Hinduja;
L., Divya Christy;
N., Paulin Reneeta;
M., Rajalakshmi

Publication type:

Abstract

A Descriptive Study on the Efficacy and Safety of Sodium Glucose Co-Transporter 2 Inhibitors as Add on Therapy in Patients with Type 2 Diabetes.

Published in:

Malaysian Journal of Medicine & Health Sciences, 2023, v. 19, p. 20

By:

Sulong, Ahmad Muzakhir;
Rus, Mohd Rafizi Mohamed;
Gnanasan, Shubashini

Publication type:

Article

Características diferenciales del empagliflozin en el tratamiento de la diabetes mellitus.

Published in:

Revista Latinoamericana de Hipertension, 2021, v. 16, n. 2, p. 163, doi. 10.5281/zenodo.5514033

By:

Aguilera Moreira, Vicente David;
Mendieta González, María Dennys;
López Pino, Adriana Victoria;
Tapia Mena, David Sebastián;
Caisa Villacrés, Virginia Zeneida;
Revelo Benavides, Karen Michel;
Araujo Egas, Carla María;
Santamaría Loza, Estefanía Carolina;
Velásquez Gutiérrez, Abraham Melquisedec

Publication type:

Article

Effect of canagliflozin alone and in combination with metformin on ovarian histology of a polycystic ovary syndrome rat model.

Published in:

Biomedica, 2023, v. 39, n. 2, p. 78, doi. 10.24911/biomedica/5-895

By:

Zaheer, Akfish

Publication type:

Article

Clinical Pharmacokinetics & Pharmacodynamics.

Published in:: Clinical Pharmacology in Drug Development, 2017, v. 6, p. 3, doi. 10.1002/cpdd.385
Publication type:: Article

Absolute Oral Bioavailability and Pharmacokinetics of Canagliflozin: A Microdose Study in Healthy Participants.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 4, p. 295, doi. 10.1002/cpdd.162

By:

Devineni, Damayanthi;
Murphy, Joseph;
Wang, Shean‐Sheng;
Stieltjes, Hans;
Rothenberg, Paul;
Scheers, Ellen;
Mamidi, Rao N.V.S.

Publication type:

Article

Effect of Food on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, and Assessment of Dose Proportionality in Healthy Participants.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 4, p. 279, doi. 10.1002/cpdd.151

By:

Devineni, Damayanthi;
Manitpisitkul, Prasarn;
Murphy, Joseph;
Stieltjes, Hans;
Ariyawansa, Jay;
Di Prospero, Nicholas A.;
Rothenberg, Paul

Publication type:

Article

Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 3, p. 226, doi. 10.1002/cpdd.166

By:

Devineni, Damayanthi;
Manitpisitkul, Prasarn;
Murphy, Joseph;
Skee, Donna;
Wajs, Ewa;
Mamidi, Rao N. V. S.;
Tian, Hong;
Vandebosch, An;
Wang, Shean-Sheng;
Verhaeghe, Tom;
Stieltjes, Hans;
Usiskin, Keith

Publication type:

Article

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kinetics.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 1, p. 12, doi. 10.1002/cpdd.115

By:

Polidori, David;
Sha, Sue;
Heise, Tim;
Natarajan, Jaya;
Artis, Eunice;
Wang, Shean‐Sheng;
Vaccaro, Nicole;
Rothenberg, Paul;
Stirban, Alin

Publication type:

Article

Trends in antidiabetic drug use in Portugal: 8 years real‐world data from a nationwide retrospective observational study (2017–2024) (TREND‐8 study).

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 7, p. 4022, doi. 10.1111/dom.16429

By:

Neves, João Sérgio;
Leite, Ana Rita;
Marcelino, Mafalda;
Melo, Miguel;
Freitas, Paula;
Ramalho, Célia;
Calçada, Eduardo

Publication type:

Article

The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP‐1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose‐escalation Phase I study.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 4, p. 2110, doi. 10.1111/dom.16203

By:

Fan, Yuxin;
Yuan, Jiandong;
Dong, Lichun;
Yu, Chongjing;
Ding, Haifeng;
Xie, Daosheng;
Guan, Runfang;
Li, Ruixia;
Zou, Wenhong;
Long, Shuxian;
Chen, Jion;
Huang, Yu;
Yang, Mei;
He, Jianchang;
Wen, Weibo

Publication type:

Article

An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, p. 5, doi. 10.1111/dom.15751

By:

Chen, Angela X.;
Fletcher, Robert;
Neuen, Brendon L.;
Neal, Bruce;
Arnott, Clare

Publication type:

Article

Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 4060, doi. 10.1111/dom.15761

By:

Rasmussen, Daniel G. K.;
Hansen, Michael K.;
Frederiksen, Peder;
Luo, Yunyun;
Pehrsson, Martin;
Neal, Bruce;
Karsdal, Morten A.;
Genovese, Federica

Publication type:

Article

Time trends and regional variation in utilization of antidiabetic medicines in China, 2015–2022.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2752, doi. 10.1111/dom.15594

By:

Zhang, Jieqiong;
Xu, Sen;
Liu, Xingyu;
Zhang, Jinwei;
Hu, Shuchen;
Liu, Xiaoyong;
Yang, Caijun;
Fang, Yu

Publication type:

Article

Patterns of initial and first‐intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010–2020: A retrospective population‐based cohort study.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2684, doi. 10.1111/dom.15584

By:

Mahmoud, Fatema;
Mueller, Tanja;
Mullen, Alexander;
Sainsbury, Christopher;
Rushworth, Gordon F.;
Kurdi, Amanj

Publication type:

Article

Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 878, doi. 10.1111/dom.15380

By:

Chen, Xi;
Hou, Xingyun;
Gao, Junling;
Yu, Xiaxia;
Zeng, Weixian;
Lv, Ronggui;
Yang, Xixiao;
Liu, Yong

Publication type:

Article

Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 758, doi. 10.1111/dom.15340

By:

Sharma, Abhinav;
Marques, Pedro;
Neuen, Brendon L.;
Fletcher, Robert A.;
Slee, April;
Rapattoni, Wally;
Ang, Fernando G.;
Arnott, Clare;
Levin, Adeera;
Verma, Subodh;
Perkovic, Vlado;
Mahaffey, Kenneth W.

Publication type:

Article

Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 441, doi. 10.1111/dom.15331

By:

Kuate Defo, Alvin;
Bakula, Veselko;
Pisaturo, Alessandro;
Labos, Christopher;
Wing, Simon S.;
Daskalopoulou, Stella S.

Publication type:

Article